financetom
Business
financetom
/
Business
/
Turboprop maker ATR to stabilize output as deliveries dip slightly
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Turboprop maker ATR to stabilize output as deliveries dip slightly
Feb 12, 2025 10:27 AM

PARIS, Feb 12 (Reuters) - The world's largest commercial

turboprop maker, Franco-Italian ATR, delivered 35 aircraft last

year, just shy of the 36 handed to customers in 2023, and said

on Wednesday it would pause efforts to ramp up production as it

addresses problems in its supply chain.

ATR, which is jointly owned by Airbus and Leonardo

, is the latest aircraft manufacturer to highlight

supply problems as the aerospace industry struggles to regain

industrial momentum after the pandemic.

It had targeted about 40 deliveries in 2024. It did not give

a numerical target for 2025, saying it would focus on

stabilising production at current levels, which are well below

the peak of around 80 aircraft a year before the pandemic.

"When I look at 2025, I would say that the context is still

very difficult so (the) supply chain situation as we see it will

remain tense in some areas, but we see some areas of

improvement," CEO Nathalie Tarnaud Laude told a press

conference.

"This year we will stabilize production at the level where

we were and start to prepare for the rampup in the second part

of the year. Our ambition is to ramp up to a high level of

production."

ATR is the dominant producer of regional turboprop planes,

with a family of aircraft seating 42 to 78 people.

The company also pushed back the target date for a proposed

hybrid-propulsion version of its family of aircraft to 2035 from

2030, citing the lack of available engine technology,

FlightGlobal reported.

The move comes days after Airbus suspended a flagship

proposal to develop a new regional hydrogen-powered aircraft for

five to 10 years.

Commercial momentum remains strong and ATR aims to continue

to add to its order book in 2025, Tarnaud Laude said.

ATR reported 56 new orders in 2024, up from 40 a year

earlier. After cancellations, it posted 53 net orders for 2024.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TJX Q3 revenue beats estimates
TJX Q3 revenue beats estimates
Nov 19, 2025
Overview * TJX Q3 FY26 revenue grows 7% yr/yr, beating analyst expectations * Q3 diluted EPS rises 12% to $1.28, exceeding company plan * Company returned $1.1 bln to shareholders via buybacks and dividends in Q3 Outlook * Company expects Q4 comp sales to rise 2% to 3% * TJX raises full-year EPS outlook to $4.63-$4.66 * Company plans $2.5...
Dana, Allison Transmission Receive Regulatory Approvals for Off-Highway Business Deal
Dana, Allison Transmission Receive Regulatory Approvals for Off-Highway Business Deal
Nov 19, 2025
07:38 AM EST, 11/19/2025 (MT Newswires) -- Dana (DAN) and Allison Transmission ( ALSN ) said Wednesday they have received all required regulatory approvals for the previously announced sale of Dana's off-highway business to Allison. The transaction is expected to close at or near the year-end, the companies said. The transaction has enabled Dana to return $600 million to shareholders...
TJ Maxx parent TJX raises annual profit forecast
TJ Maxx parent TJX raises annual profit forecast
Nov 19, 2025
(Reuters) -TJX Cos ( TJX ) raised annual profit forecast on Wednesday, anticipating that broad sourcing strategy and seasonal inventory will attract bargain-hunting shoppers to its off-price stores. Shares of the company rose about 3% in premarket trading. They have risen nearly 21% so far this year. The Framingham, Massachusetts-based company has capitalized on a seasonal shift from late-summer to...
Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy
Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy
Nov 19, 2025
07:37 AM EST, 11/19/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday the pivotal phase 3 trial of its investigational regimen of doravirine/islatravir in treatment-naive adults with HIV-1 infection met its success criterion of primary efficacy. Trial topline results showed the non-inferiority of the drug and a comparable safety profile to once-daily oral bictegravir/emtricitabine/tenofovir alafenamide, Merck ( MRK )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved